Skip to main content
. 2019 Mar 26;30(5):782–794. doi: 10.1681/ASN.2018070703

Figure 2.

Figure 2.

Ipragliflozin, but not pioglitazone, reduces NaCl cotransporter (NCC) levels in vivo in db/db mice. (A and D) Blood glucose levels in the indicated groups. In the db/db group, the blood glucose levels >700 mg/dl were regarded as 700 mg/dl. Both ipragliflozin, an sodium glucose cotransporter 2 (SGLT2) inhibitor, and pioglitazone, a Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonist, effectively reduce blood glucose levels in db/db mice but not in db/+ mice. (B and E) Effects of ipragliflozin and of pioglitazone on NCC levels in the plasma membrane–enriched fraction of the kidneys in indicated animals. Blots show biologic replicates. Dot plot graphs show the results of densitometric quantitation. (C and F) Plasma K+ levels in the indicated groups. Data are expressed as means±SEM; n=5 for db/db and db/db plus ipragliflozin, n=4 for db/db plus pioglitazone, and n=4 for db/+, db/+ plus ipragliflozin, and db/+ plus pioglitazone.